Intrarectal administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnlp-/- mice

Gene Therapy

Volumn 20, Issue 2, 2013, Pages 187-193

  Tai, E K K ^a   Wu, W K K ^a,b   Wang, X J ^a,b   Wong, H P S ^a   Yu, L ^a   Li, Z J ^a   Lee, C W ^a,b   Wong, C C M ^a   Yu, J ^a,b   Sung, J J Y ^a,b   Gallo, R L ^c   Cho, C H ^a,b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobial peptide; Cathelicidin; IL 1; Mucin; TNF; Ulcerative colitis

Indexed keywords

CATHELICIDIN; DEXTRAN SULFATE; INTERLEUKIN 1BETA; MUCIN; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; IN VIVO STUDY; MALE; MOUSE; MUCUS SECRETION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; APOPTOSIS; COLITIS, ULCERATIVE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MICE; MICE, KNOCKOUT; MUCINS; PEROXIDASE; PLASMIDS; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 84873568452     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.22     Document Type: Article

References (31)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 454: 307-317
2. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474: 298-306
3. Gibson PR, Muir JG. Reinforcing the mucus: A new therapeutic approach for ulcerative colitis? Gut 2005; 54: 900-903 (Pubitemid 40873897)
4. Pullan RD, Thomas GA, Rhodes M, Newcombe RG, Williams GT, Allen A et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994; 35: 353-359 (Pubitemid 24092905)
5. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-129 (Pubitemid 44015753)
6. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135
7. Sasaki M, Mathis JM, Jennings MH, Jordan P, Wang Y, Ando T et al. Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. J Inflamm (Lond) 2005; 2: 13
8. Domenech E. Inflammatory bowel disease: Current therapeutic options. Digestion 2006; 73 (Suppl 1): 67-76
9. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816
10. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 2002; 70: 953-963 (Pubitemid 34083859)
11. Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, Haikel Y, Chich JF. Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. Curr Pharm Des 2010; 16: 1024-1039
12. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192: 1069-1074
13. Wu WK, Wong CC, Li ZJ, Zhang L, Ren SX, Cho CH. Cathelicidins in inflammation and tissue repair: Potential therapeutic applications for gastrointestinal disorders. Acta Pharmacol Sin 2010; 31: 1118-1122
14. Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem 2006; 281: 1636-1643
15. Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T et al. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 2003; 307: 146-151 (Pubitemid 37151900)
16. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood) 2007; 232: 799-808 (Pubitemid 46827822)
17. Koon HW, Shih DQ, Chen J, Bakirtzi K, Hing TC, Law I et al. Cathelicidin signaling via the toll-like receptor protects against colitis in mice. Gastroenterology 2011; 141: 1852-1863. e3
18. Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006; 18: 615-621 (Pubitemid 43804644)
19. Kanbe T, Murai R, Mukoyama T, Murawaki Y, Hashiguchi K, Yoshida Y et al. Naked gene therapy of hepatocyte growth factor for dextran sulfate sodium-induced colitis in mice. Biochem Biophys Res Commun 2006; 345: 1517-1525 (Pubitemid 43833441)
20. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications. Curr Opin Gastroenterol 2007; 23: 379-383 (Pubitemid 46878948)
21. Corfield AP, Wagner SA, Clamp JR, Kriaris MS, Hoskins LC. Mucin degradation in the human colon: Production of sialidase, sialate O-acetylesterase, N-acetylneuraminate lyase, arylesterase, and glycosulfatase activities by strains of fecal bacteria. Infect Immun 1992; 60: 3971-3978
22. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992; 102: 529-537
23. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767
24. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-826
25. Bouguen G, Chevaux JB, Peyrin-Biroulet L. Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases. World J Gastroenterol 2011; 17: 547-556
26. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454-457 (Pubitemid 34173727)
27. Liu ES, Ye YN, Shin VY, Yuen ST, Leung SY, Wong BC et al. Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis 2003; 24: 1407-1413 (Pubitemid 37038830)
28. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249
29. Guo X, Wang WP, Ko JK, Cho CH. Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats. Gastroenterology 1999; 117: 884-892 (Pubitemid 29468231)
30. Ma L, Wang WP, Chow JY, Lam SK, Cho CH. The role of polyamines in gastric mucus synthesis inhibited by cigarette smoke or its extract. Gut 2000; 47: 170-177 (Pubitemid 30489758)
31. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501